Pharmaceutical Industry News Archive
Get news by email or subscribe to our news feeds.
News Archive for January 2011
January 3, 2011
- Advanced Life Sciences to Explore Strategic Alternatives to Maximize Shareholder Value
- J&J Helps Develop Blood Test to Spot 1 Cancer Cell in a Billion Healthy Ones
- FDA's Drug Approval Down in 2010
- Firms Fight Move to Cheap Anti-Blindness
- Cumberland Pharmaceuticals Announces Voluntary Recall of Acetadote Vials
- Sigma-Aldrich Acquires Cerilliant Corporation to Strengthen its Analytical Chemistry Portfolio
- GSK Responds to 60 Minutes
- Boston Scientific Completes Sale of Neurovascular Business
January 4, 2011
- Santaris Pharma A/S Announces Expanded Worldwide Strategic Alliance With Pfizer Inc. Directed to Development of RNA-targeted Medicines
- Pfizer Anti-Smoking Drug Demand Soars
- Celgene Seeks Approval for Blood Cancer Treatments
- Celgene Provides Update on Regulatory Submissions
- FDA Authorizes Alferon LDO Clinical Study for Treatment and Prevention of Influenza
January 5, 2011
- Teva Completes Acquisition of Théramex
- arGEN-X Signs Discovery and Development Alliance With Lilly
- Bayer AG Seeks EU Approval for New Blood Thinner
- 41 Million Dollar Market for Mobile Phone Medical Apps
- UCB's Financial Update 2010
- Viropro, Inc. Signs a Binding Letter of Agreement For a Multi Million Development Contract With NASDAQ Listed Spectrum Pharmaceuticals, Inc.
- UK Pregnant Women Say Contraceptive Doesn't Work
January 6, 2011
- Biogen Idec Appoints Doug Williams to Head R&D, Steven Holtzman to Head Corporate Development
- Salix Drug Helps Irritable Bowel Syndrome
- CVS Caremark Study Finds Medication Adherence Leads to Lower Health Care Costs, Even After Accounting for Increased Prescription Drug Spending
- Immutep and GlaxoSmithKline sign licence agreement for IMP731, a novel therapeutic antibody for the treatment of autoimmune diseases
- Plexxikon Signs Agreement With Genentech to Co-Promote PLX4032 in the US
- FDA Launches Website To Help Regulated Industries Save Time, Resources
- Affymax Says Orwin Will Replace Morris As CEO
- Amgen and Xencor Enter Option Deal to Co-Develop Xencor's Novel Antibody for Autoimmune Diseases
- Regulators Accept Merck Drug For Expedited Review
January 7, 2011
- Novartis International AG (CH) - Novartis Gains New Indication for Lucentis in EU for Vision Loss due to Diabetic Macular Edema, a Leading Cause of Blindness
- Teva Pharmaceuticals, U.S.A issues a voluntary nationwide recall of Metronidazole Tablets USP, 250mg Due to Low Weight Tablets
- KOMBIGLYZE XR (Saxagliptin and Metformin HCl Extended-Release) Tablets, a New Treatment for Type 2 Diabetes Mellitus in Adults, Now Available in U.S. Pharmacies
January 10, 2011
- California Backs Class-Action Suit Against Drug Giants
- Supreme Court Grants Vermont Request to Review Data Mining Case
- Former Pfizer Scientists Put Down Biotech Roots
- Pfizer Agrees to Collaborate With Sutro Biopharma
- Astellas to Review Strategic Business Alternatives for Prosidion Subsidiary
- Amgen Says Court Upholds Sensipar Patents
- Kythera and Intendis Announce Initiation of European Phase III Clinical Development Program to Evaluate ATX-101 for Reduction of Submental Fat
- Genzyme Statement on Discussions With Sanofi-Aventis
- Sandoz Announces Phase II Clinical Trial for Biosimilar Version of Leading Monoclonal Antibody Rituximab
- Thermo Fisher Scientific Announces HSR Clearance to Acquire Dionex
- Optimer Pharmaceuticals Appoints Hank McKinnell to Its Board of Directors
January 11, 2011
- Lilly and Boehringer Ingelheim Announce Strategic Alliance to Bring New Diabetes Treatments to Patients Worldwide
- Galapagos receives ?7.4 M milestone in arthritis alliance with GlaxoSmithKline
- Takeda and Zinfandel Pharmaceuticals Sign Licensing Agreement for Alzheimer's Disease Biomarker in Combination with Pioglitazone
- Epizyme Signs Development Deal With Glaxo
- Abbott to Launch First Absorbable Stent In Europe
- Danish Neurosearch to Trim Workforce In Reorganization
- Gilead Sciences Extends Study of HIV Drug
- PDL Patent Claim Invalidated, Shares Slump
- Madison Drug Developer Raises $1.25 Million
- Bristol-Myers, Pharmasset Plan Hepatitis C Study
- Manhattan Research Releases Study Exploring How European Physicians Use Technology for Professional Purposes and Pharma Interaction
- Genzyme Financial Recovery Continues in Fourth Quarter
January 12, 2011
- The World?s Largest Healthcare Communications Network Releases Survey Findings, Unveiling Predictions for Healthcare Marketing in 2011
- Vaccine For Shingles Ailment Effective -- And Seldom Used, Study Says
- Eurand, Nycomed Reach Marketing Deal For Zenpep
- Merck, Parexel Reach Biosimilar Development Deal
- Shingles Vaccine Associated With 55 Percent Reduced Risk of Disease
- Isis Chief Says Sanofi Likely to Reach Deal With Genzyme
- Sanofi-aventis Enters Into Two Research & Development Collaborations With the University of California, San Francisco
- Sanofi CEO 'Committed' to Buying Genzyme
- Omnicom Group's Diversified Agency Services Acquires Pioneering Corporate Licensing Agency Nancy Bailey & Associates
January 13, 2011
- FDA Drug Safety Communication: Update to ongoing safety review of Lantus (insulin glargine) and possible risk of cancer
- FDA Drug Safety Communication: Update to ongoing safety review of Lantus (insulin glargine) and possible risk of cancer
- KV Faces Setback After FDA Delays Approval of Key Drug
- Panelists Vote Down Lilly Drug For Digestion Issue
- Eisai Opens for Business in the Netherlands
- Pfizer Manufacturing Steady in Rouses Point
- KV in Cash Crisis With Few Options
- FDA Limits Acetaminophen in Prescription Combination Products; Requires Liver Toxicity Warnings
- Merck Statement on Changes to Clinical Studies of Vorapaxar
- Sucampo Announces Resignation of Chief Financial Officer
- Oregon Sues Johnson & Johnson for Leaving Flawed Motrin on Store Shelves
- EU Clears Sanofi-Aventis to Buy US Genzyme
- ICTS Patient Recruitment Announces Board Changes
- Simcere Pharmaceutical Group Announces Resignation of CFO Frank Zhao
January 14, 2011
- Genentech Informs Customers of Important Information About Triad Group's Alcohol Prep Pads
- Cumberland Gets Approval of New Acetadote Formula
- Inverse Benefits Due to Drug Marketing Undermine Patient Safety And Public Health
- AstraZeneca's Brilinta Could Benefit From Problems at Rival Merck
- FDA Warns Of Liver Damage With Sanofi Drug
- FDA Drug Safety Communication: Severe Liver Injury Associated With the Use of Dronedarone (Marketed As Multaq)
- Sanofi-Aventis Considers Offering $76 Per Share for Genzyme
- Evonik and Boehringer Ingelheim Have Signed An Agreement on the Sale of the Resomer Business to Evonik
- Study: Advocacy Groups Avoid Revealing Drug Company Funds
- Technological Advances Drive & Change Top Therapeutic Areas: PharmaLive Special Report
January 18, 2011
- Magnetically Controlled Pills Could Boost Body's Absorption of Drugs
- New Drugs Take Aim At Hepatitis C, Spur Debate on Whether to Test Baby Boomers
- GSK Set for 2.2 Billion Pound Legal Charge
- Astellas Enters Into License Agreement With Tolmar
- Merck Serono and Domain Therapeutics Announce an Agreement to Develop Drugs for Parkinson's Disease
- Forest Laboratories, Inc. Reports Fiscal Third Quarter 2011 Earnings Per Share of $1.11 Including a $0.23 Per Share Charge for a New Product Licensing Fee
- Ariad Pharma Cancer Drug Study Meets Main Goal
- GlaxoSmithKline Announces Q4 2010 Legal Charge
- IMS Health Issued the Following Statement Regarding Its Pending Acquisition of SDI
- Antitrust: Commission Launches Second Monitoring Exercise of Patent Settlements in Pharma Sector
- Federal Government Obtains Permanent Injunction Against Deltex Pharmaceuticals Inc.
January 19, 2011
- Amgen Sells Bay Area Facility
- Companies Won't Sell Kentucky Execution Drug
- Depomed, Abbott Labs Seek to Resolve Dispute
- Theraclone and Pfizer Enter into Infectious Disease and Cancer Antibody Discovery Collaboration
- Depomed Will Engage in Mediation to Resolve Dispute With Abbott; Comments on DM-1796 Regulatory Status and Orphan Drug Designation
- Boehringer Ingelheim to Purchase Amgen's Fremont (California) Facility
- U. Mich. Opening Incubator in Former Pfizer Site
- Amgen Sells Bay Area Facility
- Depomed, Abbott Labs Seek to Resolve Dispute
- Boston Scientific to Acquire Atritech
- Impax Laboratories Corrects Inaccurate Information about Product Pipeline Opportunities Discussed in Several Financial Articles Circulated on the Internet
January 20, 2011
- No Evidence That Statins Benefit 'Worried Well' Patients, Says Study
- Sanofi-Aventis May Prolong Offer For US Genzyme
- Appeals Court Revives Lawsuit Against KV
- Merck: Drug Did Have Bleed Risk in Stroke Patients
- Genzyme to Build Additional Plant to Support Growth of Myozyme and Lumizyme
- Novo Nordisk Intends to Appeal Adverse Ruling in Prandin (repaglinide) Patent Case
- Cognizant Selected by Lilly to Deliver Commercial Operations Solutions to Enhance Sales and Marketing Effectiveness, Business Performance
- FDA Requests More Trials for Mannkind Insulin
- Vertex Says FDA Will Rule on Telaprevir By May 23
- Ziopharm says lymphoma drug may get EU incentives
- Forest Labs says depression drug fails in study
January 21, 2011
- inVentiv Health to Acquire Leading Management Consulting Firm, Campbell Alliance, and Global CRO Organization, i3
- Pfizer Extends Tender Offer to Acquire King Pharmaceuticals, Inc. to January 28, 2011
- FDA Checking 36 Fever-Related Seizures in Children After Flu Shot
- Vivus Says FDA Asks About Qnexa Birth Defect Link
- Review of the Manufacture of Baxter?s Peritoneal Dialysis Solutions Initiated
- Commonwealth Biotechnologies, Inc. Announces Filing for Reorganization Under Chapter 11 Bankruptcy
- AstraZeneca Adds 1% on New Brilinta Hopes, As FTSE 100 Rebounds
- Research: Rapidly Deteriorating Growth for Pharma
- NeoStem Acquires Progenitor Cell Therapy
- Archimedes, Inc. and FDA Announce Collaboration to Evaluate the Clinical Risks and Benefits of Weight Loss Medications
January 24, 2011
- Sanofi-Aventis Extends Again $18.5 Billion Takeover Bid for Genzyme
- Teva Starts Lawsuit Against Astrazeneca Over Seroquel, Paper Says
- Novartis Bids $470 Million For US Cancer Diagnostic Firm
- CenterWatch Expands its www.centerwatch.com Service to Assist Patients and Health care Professionals in Finding Clinical Trials
- MorphoSys Announces Clinical Milestone within Boehringer Ingelheim Alliance
- Novartis Announces Agreement to Acquire Genoptix, Inc. in All Cash Offer
- US Centre Hopes to Spur Drug Research That Promotes Follow-Up to Promising Discoveries
- Important Information for ARIXTRA Starter Kit Patients Regarding Triad Group's Alcohol Prep Products
January 25, 2011
- Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer
- Amgen's Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21
- Mylan Announces Lipitor Settlement Agreement
- Johnson & Johnson Reports 2010 Fourth-Quarter and Full-Year Results
- Teva Receives FDA Action Letter For Generic Lovenox
- Completion of Long-Term Phase 3 Safety Trial for Latuda (lurasidone HCl)
- Mylan Announces Caduet Settlement Agreement
- Amgen Q4 Profit Up 10 Per Cent, Buys Cancer Drug Maker Biovex in $1B Deal
January 26, 2011
- Mitsubishi Tanabe Pharma Starts Voluntary Recall of Injection Solution Products
- Abbott Reports Double-Digit Sales and Ongoing Earnings Growth in Fourth Quarter; Issues Strong Ongoing Earnings Outlook for 2011
- Gilead Sciences Announces Fourth Quarter and Full Year 2010 Financial Results
- Bristol-Myers Squibb and sanofi-aventis Announce U.S. FDA Decision to Grant Pediatric Exclusivity For Plavix
- Top N.Y.-Based Hospitals Join Pfizer Research Venture
- Glaxo Takes Steps to Polish Image
- Pwc Advising Pfizer On Sell-Off
- Gilead Sciences 4Q Profit Falls on Buyout Costs
- QPS Expands Phase 1 and Bioanalytical Capability by Acquisition of Bioserve, India
- Bristol-Myers to Keep a Seattle Presence
- Teva to Acquire Corporación Infarmasa
- John J. Horan, Former Merck Chairman and CEO Dies of Natural Causes at 90 Years of Age
January 27, 2011
- Alcon Posts Solid Fourth Quarter Financial Results
- Lilly Reports Fourth-Quarter and Full-Year 2010 Results, Provides 2011 Financial Guidance
- Baxter Reports Sales and EPS for Fourth Quarter 2010 in Line with Guidance
- Novartis Q4 Profit Down As Vaccine Demand Drops
- Innovation drives Novartis to double-digit growth for 2010
- AstraZeneca Profit Down on Heavy Competition in US
- Lawmakers Consider Barring Gifts to Physicians
- Lake County, Illinois Worried About Impact Of Abbott Layoffs
- Kohl, Grassley: Stopping "Pay-For-Delay" Deals Essential to Lowering Rx Drug Costs
- Kohl Urges Prompt Action on FDA Drug Labeling for Pregnant Women and New Mothers
- CyDex Pharmaceuticals Approves Merger with Ligand Pharmaceuticals
- Bristol-Myers Squibb Delivers Solid Fourth Quarter Results in a Year Highlighted by Robust Clinical Data, Continued Execution of Strategic Transactions and Good Operating Performance
- China's Ministry of Commerce Grants Clearance for Merger of BMP Sunstone and Sanofi-aventis Subsidiary
- Altra Investments and The Rohatyn Group Sell Controlling Stake in Infarmasa
- Arena Pharmaceuticals Announces Workforce Reduction and Provides Lorcaserin Regulatory Update
January 28, 2011
- Sanofi-Aventis Says Cancer Drug Has Little Effect
- Arena Pharma Says It Will Cut 66 US Jobs
- Early Successful Readout of Tarceva Study in a Distinct Form of Lung Cancer
- Actelion and GSK Discontinue Clinical Development of Almorexant
- Bayer and Zydus Cadila sign Joint Venture Agreement to strengthen pharmaceutical business in India
- Pfizer Announces HSR Clearance for the Acquisition of King Pharmaceuticals
- BioTime Acquires Assets of Cell Targeting, Inc.
- U.S. Subsidiary H3 Biomedicine Inc. Undertakes the Development of Next-Generation Cancer Drugs
- Understanding the Impact of a Sanofi-Aventis/Genzyme Merger: PharmaLive Special Report
January 31, 2011
- Merck Considers Divestment of Non-Prescription Drug Arm
- Genzyme Will Allow Sanofi-Aventis to Conduct Due Diligence
- Pfizer Completes Tender Offer For Shares Of King Pharmaceuticals, Inc.
- Mother Blames Drugs Company for Daughter's Severe Disability
- Texas Jury Orders Johnson & Johnson to Pay $482 Million in Patent Dispute Over Cardiac Stents
- NPS Pharma Shares Jump on Drug Study Results
- Novartis Pharmaceuticals Corporation Sentenced for Off-Label Drug Marketing
- Alexion Acquires Taligen Therapeutics and Creates Translational Medicine Group to Accelerate Development of Expanded Portfolio
- Dr. Reddy's Provides Update on the Fexofenadine-Pseudoephedrine 24 Hour Litigation
- Which Pharma Product Websites are Driving Consumers to the Doctor to Request Prescriptions?
